Pricing pressure in generics may persist
Management acknowledged pricing pressure in large volume generics due to inventory destocking by mid-to-small players, which could last up to two years.
medium · management_commentary
Divi's Laboratories — Q2 FY24
Divis Laboratories reported Q2 FY24 consolidated PAT of INR 348 crore on total income of INR 1,995 crore, with export share at 87%.
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Inventory write-offs from COVID leftovers
INR 20 crore inventory write-off was taken for COVID-related materials, indicating potential for further write-offs if demand does not recover.
low · management_commentaryCustom synthesis growth not yet visible YoY
Despite management optimism, custom synthesis revenue appears flat YoY when adjusting for COVID sales, raising questions about growth trajectory.
medium · analyst_questionGeopolitical and economic fluctuations
Management cited potential consequences from ongoing geopolitical and economic fluctuations, though no specific impact was quantified.
low · management_commentary